Intracellular mechanisms of microglia activation in diet-induced obesity
Project Number7R01DK120321-04
Former Number5R01DK120321-03
Contact PI/Project LeaderDIANO, SABRINA
Awardee OrganizationCOLUMBIA UNIVERSITY HEALTH SCIENCES
Description
Abstract Text
Microglia, the yolk sack-derived monocytes of the brain and spinal cord, plays a crucial role in immune
responses, including inflammation. Recent work has expanded the role of microglia in the central nervous
system (CNS), which includes phagocytosis of axon terminals and dendritic spines, thus pointing to an active
role of microglia in neuronal circuit development and plasticity (Tremblay et al., 2011). Diet-induced obesity
(DIO) induces microglia activation and hypothalamic inflammation as early as 3 days after high fat diet (HFD)
exposure, before changes in body weight occur (Thaler et al., 2012). We
in
control
also showed that activated microglia
the hypothalamus act as a conductor of synaptic plasticity of the hypothalamic neurocircuitry involved in the
of feeding behavior and glucose metabolism (Jin et al., 2016).Changes in microglial activity and
function are processes that require dynamic changes in energy demand. During inflammation, changes in
mitochondrial metabolism were suggested to contribute to microglia activation (Voloboueva et al., 2013;
Gimeno-Bayon et al., 2014; Orihuela et al., 2016). Our preliminary data revealed that HFD-induced
hypothalamic inflammation and microglia activation is paralleled by increased mitochondrial uncoupling protein
2 (UCP2) expression and a rapid (within 3 days) and transient (by day 7 days it is reversed) mitochondria
fission event in microglia cells. We have previously shown that UCP2 propagates mitochondrial fission
(Coppola et al., 2007; Andrews et al., 2008; Toda et al., 2016) via activation of dynamic-related peptide 1
(DRP1), a mitochondrial fission enabler (Toda et al., 2016). Corresponding with this, when we deleted UCP2
selectively from microglia in adult mice, HFD-exposure failed to trigger fission of mitochondria in hypothalamic
microglia cells, and, it also diminished HFD-induced body weight gain and metabolic impairments of mice.
Taken together these observations gave impetus to the central hypothesis of this proposal which is that DRP1
mediated mitochondrial fission via DRP1 activation in the early but not late phase of HFD feeding is
indispensible for microglia activation, neuroinflammation, hypothalamic circuit adaptation to promote
obesity. To test these hypotheses, we propose 3 Aims: Specific Aim 1 will test the hypothesis that UCP2-
induced mitochondrial fission mediated by DRP1 activation in the early phase (by day 3) of HFD
feeding is critical for hypothalamic microglia activation, inflammation and obesity susceptibility.
Specific Aim 2 will test the hypothesis that HFD-induced microglia activation requires DRP1 for the
rapid and transient mitochondria fission event in microglia cells in early but not late phase of HFD
feeding to promote obesity. Specific Aim 3 will determine whether activated microglia in HFD-fed DIO
mice are upstream controllers of synaptic adaptations of arcuate POMC and AgRP neurons.
The execution of these studies will deliver novel insights into central regulation of whole body glucose
metabolism and offer novel avenues to combat diabetes by targeting brain mitochondrial dynamics.
Public Health Relevance Statement
To understand the etiology of metabolic disorders, including obesity and type II diabetes,
it is essential that we gain better insight into the mechanisms used by the central
nervous system to regulate metabolism. The experiments proposed in this application
will unmask the role of mitochondrial dynamics and UCP2 in microglia activation in the
central regulation of energy homeostasis and will help us to better develop strategy for
the treatment of metabolic disorders.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
621889815
UEI
QHF5ZZ114M72
Project Start Date
01-September-2020
Project End Date
30-June-2022
Budget Start Date
01-September-2020
Budget End Date
30-June-2021
Project Funding Information for 2020
Total Funding
$461,318
Direct Costs
$284,764
Indirect Costs
$176,554
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Diabetes and Digestive and Kidney Diseases
$461,318
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01DK120321-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01DK120321-04
Patents
No Patents information available for 7R01DK120321-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01DK120321-04
Clinical Studies
No Clinical Studies information available for 7R01DK120321-04
News and More
Related News Releases
No news release information available for 7R01DK120321-04
History
No Historical information available for 7R01DK120321-04
Similar Projects
No Similar Projects information available for 7R01DK120321-04